Altered expression of inflammation-associated genes in oviductal cells following follicular fluid exposure: Implications for ovarian carcinogenesis

Experimental Biology and Medicine

Volumn 239, Issue 1, 2014, Pages 24-32

  Lau, Angela ^a,b   Kollara, Alexandra ^a,b   John, Elizabeth St ^c   Tone, Alicia A ^d   Virtanen, Carl ^e   Greenblatt, Ellen M ^a,b   King, W Allan ^c   Brown, Theodore J ^a,b  

^a MOUNT SINAI HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF GUELPH   (Canada)

^d PRINCESS MARGARET HOSPITAL   (Canada)

^e UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

bovine; Fallopian tube; follicular fluid; inflammatory genes; ovarian cancer

Indexed keywords

CHORIONIC GONADOTROPIN; CYCLOOXYGENASE 2; GLUCOCORTICOID RECEPTOR; GLUTATHIONE PEROXIDASE 3; INTERLEUKIN 6; INTERLEUKIN 8; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; SUPEROXIDE DISMUTASE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FOXJ1; TRANSCRIPTION FACTOR PAX8; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; VIMENTIN; TUMOR PROTEIN;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; CATTLE; CLINICAL ARTICLE; CONTROLLED STUDY; DAB2 GENE; EPITHELIUM CELL; EXPOSURE; FEMALE; GENE; GENE EXPRESSION; HUMAN; IMMUNOCYTOCHEMISTRY; INFLAMMATION; NONHUMAN; OOCYTE RETRIEVAL; OVARY FOLLICLE FLUID; OVARY TUMOR; OVIDUCT; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; ANIMAL; BIOSYNTHESIS; BOVINAE; CELL CULTURE; CLINICAL TRIAL; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; METABOLISM; PATHOLOGY;

ANIMALS; CATTLE; CELLS, CULTURED; FEMALE; FOLLICULAR FLUID; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INFLAMMATION; NEOPLASM PROTEINS; OVARIAN NEOPLASMS; OVIDUCTS; TRANSCRIPTION, GENETIC;

EID: 84891956388     PISSN: 15353702     EISSN: 15353699     Source Type: Journal    
DOI: 10.1177/1535370213508216     Document Type: Article

References (47)

1. Karst AM, Drapkin R. Ovarian cancer pathogenesis: a model in evolution. J Oncol 2010:932371.
2. Chen S,Parmigiani G.Meta-analysis of BRCA1 and BRCA2 penetrance.J Clin Oncol. 2007;25:1329-33.
3. Sogaard M,Kjaer SK,Gayther S.Ovarian cancer and genetic susceptibility in relation to the BRCA1 and BRCA2 genes. Occurrence, clinical importance and intervention.Acta Obstet Gynecol Scand. 2006;85:93-105.
4. Hunn J,Rodriguez GC.Ovarian cancer: etiology, risk factors, and epidemiology.Clin Obstet Gynecol. 2012;55:3-23.
5. McGuire V,Felberg A,Mills M,Ostrow KL,DiCioccio R,John EM,West DW,Whittemore AS.Relation of contraceptive and reproductive history to ovarian cancer risk in carriers and noncarriers of BRCA1 gene mutations.Am J Epidemiol. 2004;160:613-18.
6. McLaughlin JR,Risch HA,Lubinski J,Moller P,Ghadirian P,Lynch H,Karlan B,Fishman D,Rosen B,Neuhausen SL,Offit K,Kauff N,Domchek S,Tung N,Friedman E,Foulkes W,Sun P,Narod SA.Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study.Lancet Oncol. 2007;8:26-34.
7. McLemore MR,Miaskowski C,Aouizerat BE,Chen LM,Dodd MJ.Epidemiological and genetic factors associated with ovarian cancer.Cancer Nurs. 2009;32:281-8.
8. Tung KH,Wilkens LR,Wu AH,McDuffie K,Nomura AM,Kolonel LN,Terada KY,Goodman MT.Effect of anovulation factors on pre- and postmenopausal ovarian cancer risk: revisiting the incessant ovulation hypothesis.Am J Epidemiol. 2005;161:321-9.
9. Crum CP,Drapkin R,Miron A,Ince TA,Muto M,Kindelberger DW,Lee Y.The distal fallopian tube: a new model for pelvic serous carcinogenesis.Curr Opin Obstet Gynecol. 2007;19:3-9.
10. Piek JM,van Diest PJ,Zweemer RP,Jansen JW,Poort-Keesom RJ,Menko FH,Gille JJ,Jongsma AP,Pals G,Kenemans P,Verheijen RH.Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer.J Pathol. 2001;195:451-6.
11. Lee Y,Miron A,Drapkin R,Nucci MR,Medeiros F,Saleemuddin A,Garber J,Birch C,Mou H,Gordon RW,Cramer DW,McKeon FD,Crum CP.A candidate precursor to serous carcinoma that originates in the distal fallopian tube.J Pathol. 2007;211:26-35.
12. Carlson JW,Miron A,Jarboe EA,Parast MM,Hirsch MS,Lee Y,Muto MG,Kindelberger D,Crum CP.Serous tubal intraepithelial carcinoma: its potential role in primary peritoneal serous carcinoma and serous cancer prevention.J Clin Oncol. 2008;26:4160-5.
13. Kindelberger DW,Lee Y,Miron A,Hirsch MS,Feltmate C,Medeiros F,Callahan MJ,Garner EO,Gordon RW,Birch C,Berkowitz RS,Muto MG,Crum CP.Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship.Am J Surg Pathol. 2007;31:161-9.
14. Tang S,Onuma K,Deb P,Wang E,Lytwyn A,Sur M,Daya D.Frequency of serous tubal intraepithelial carcinoma in various gynecologic malignancies: a study of 300 consecutive cases.Int J Gynecol Pathol. 2012;31:103-10.
15. Seidman JD,Zhao P,Yemelyanova A."Primary peritoneal" high-grade serous carcinoma is very likely metastatic from serous tubal intraepithelial carcinoma: assessing the new paradigm of ovarian and pelvic serous carcinogenesis and its implications for screening for ovarian cancer.Gynecol Oncol. 2011;120:470-3.
16. Finch A,Shaw P,Rosen B,Murphy J,Narod SA,Colgan TJ.Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers.Gynecol Oncol. 2006;100:58-64.
17. Kuhn E,Kurman RJ,Vang R,Sehdev AS,Han G,Soslow R,Wang TL,Shih Ie M.TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high-grade serous carcinoma-evidence supporting the clonal relationship of the two lesions.J Pathol. 2012;226:421-6.
18. Tone AA,Begley H,Sharma M,Murphy J,Rosen B,Brown TJ,Shaw PA.Gene expression profiles of luteal phase fallopian tube epithelium from BRCA mutation carriers resemble high-grade serous carcinoma.Clin Cancer Res. 2008;14:4067-78.
19. Tone AA,Virtanen C,Shaw P,Brown TJ.Prolonged postovulatory proinflammatory signaling in the fallopian tube epithelium may be mediated through a BRCA1/DAB2 axis.Clin Cancer Res. 2012;18:4334-44.
20. Buscher U,Chen FC,Kentenich H,Schmiady H.Cytokines in the follicular fluid of stimulated and non-stimulated human ovaries; is ovulation a suppressed inflammatory reaction?.Hum Reprod. 1999;14:162-6.
21. Revelli A,Delle Piane L,Casano S,Molinari E,Massobrio M,Rinaudo P.Follicular fluid content and oocyte quality: from single biochemical markers to metabolomics.Reprod Biol Endocrinol. 2009;7:40-40.
22. Karihtala P,Soini Y,Vaskivuo L,Bloigu R,Puistola U.DNA adduct 8-hydroxydeoxyguanosine, a novel putative marker of prognostic significance in ovarian carcinoma.Int J Gynecol Cancer. 2009;19:1047-51.
23. Lu H,Ouyang W,Huang C.Inflammation, a key event in cancer development.Mol Cancer Res. 2006;4:221-33.
24. Valavanidis A,Vlachogianni T,Fiotakis C.8-hydroxy-2′ -deoxyguanosine (8-OHdG): a critical biomarker of oxidative stress and carcinogenesis.J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 2009;27:120-39.
25. Levanon K,Ng V,Piao HY,Zhang Y,Chang MC,Roh MH,Kindelberger DW,Hirsch MS,Crum CP,Marto JA,Drapkin R.Primary ex vivo cultures of human fallopian tube epithelium as a model for serous ovarian carcinogenesis.Oncogene. 2010;29:1103-13.
26. Fotheringham S,Levanon K,Drapkin R.Ex vivo culture of primary human fallopian tube epithelial cells.J Vis Exp. 2011; (51): 2728-2728.
27. Elsik CG,Tellam RL,Worley KC,Gibbs RA,Muzny DM,Weinstock GM,Adelson DL,Eichler EE,Elnitski L,Guigo R,Hamernik DL,Kappes SM,Lewin HA,Lynn DJ,Nicholas FW,Reymond A,Rijnkels M,Skow LC,Zdobnov EM,Schook L,Womack J,Alioto T,Antonarakis SE,Astashyn A,Chapple CE,Chen HC,Chrast J,Camara F,Ermolaeva O,Henrichsen CN,Hlavina W,Kapustin Y,Kiryutin B,Kitts P,Kokocinski F,Landrum M,Maglott D,Pruitt K,Sapojnikov V,Searle SM,Solovyev V,Souvorov A,Ucla C,Wyss C,Anzola JM,Gerlach D,Elhaik E,Graur D,Reese JT,Edgar RC,McEwan JC,Payne GM,Raison JM,Junier T,Kriventseva EV,Eyras E,Plass M,Donthu R,Larkin DM,Reecy J,Yang MQ,Chen L,Cheng Z,Chitko-McKown CG,Liu GE,Matukumalli LK,Song J,Zhu B,Bradley DG,Brinkman FS,Lau LP,Whiteside MD,Walker A,Wheeler TT,Casey T,German JB,Lemay DG,Maqbool NJ,Molenaar AJ,Seo S,Stothard P,Baldwin CL,Baxter R,Brinkmeyer-Langford CL,Brown WC,Childers CP,Connelley T,Ellis SA,Fritz K,Glass EJ,Herzig CT,Iivanainen A,Lahmers KK,Bennett AK,Dickens CM,Gilbert JG,Hagen DE,Salih H,Aerts J,Caetano AR,Dalrymple B,Garcia JF,Gill CA,Hiendleder SG,Memili E,Spurlock D,Williams JL,Alexander L,Brownstein MJ,Guan L,Holt RA,Jones SJ,Marra MA,Moore R,Moore SS,Roberts A,Taniguchi M,Waterman RC,Chacko J,Chandrabose MM,Cree A,Dao MD,Dinh HH,Gabisi RA,Hines S,Hume J,Jhangiani SN,Joshi V,Kovar CL,Lewis LR,Liu YS,Lopez J,Morgan MB,Nguyen NB,Okwuonu GO,Ruiz SJ,Santibanez J,Wright RA,Buhay C,Ding Y,Dugan-Rocha S,Herdandez J,Holder M,Sabo A,Egan A,Goodell J,Wilczek-Boney K,Fowler GR,Hitchens ME,Lozado RJ,Moen C,Steffen D,Warren JT,Zhang J,Chiu R,Schein JE,Durbin KJ,Havlak P,Jiang H,Liu Y,Qin X,Ren Y,Shen Y,Song H,Bell SN,Davis C,Johnson AJ,Lee S,Nazareth LV,Patel BM,Pu LL,Vattathil S,Williams RL,Curry S,Hamilton C,Sodergren E,Wheeler DA,Barris W,Bennett GL,Eggen A,Green RD,Harhay GP,Hobbs M,Jann O,Keele JW,Kent MP,Lien S,McKay SD,McWilliam S,Ratnakumar A,Schnabel RD,Smith T,Snelling WM,Sonstegard TS,Stone RT,Sugimoto Y,Takasuga A,Taylor JF,Van Tassell CP,Macneil MD,Abatepaulo AR,Abbey CA,Ahola V,Almeida IG,Amadio AF,Anatriello E,Bahadue SM,Biase FH,Boldt CR,Carroll JA,Carvalho WA,Cervelatti EP,Chacko E,Chapin JE,Cheng Y,Choi J,Colley AJ,de Campos TA,De Donato M,Santos IK,de Oliveira CJ,Deobald H,Devinoy E,Donohue KE,Dovc P,Eberlein A,Fitzsimmons CJ,Franzin AM,Garcia GR,Genini S,Gladney CJ,Grant JR,Greaser ML,Green JA,Hadsell DL,Hakimov HA,Halgren R,Harrow JL,Hart EA,Hastings N,Hernandez M,Hu ZL,Ingham A,Iso-Touru T,Jamis C,Jensen K,Kapetis D,Kerr T,Khalil SS,Khatib H,Kolbehdari D,Kumar CG,Kumar D,Leach R,Lee JC,Li C,Logan KM,Malinverni R,Marques E,Martin WF,Martins NF,Maruyama SR,Mazza R,McLean KL,Medrano JF,Moreno BT,More DD,Muntean CT,Nandakumar HP,Nogueira MF,Olsaker I,Pant SD,Panzitta F,Pastor RC,Poli MA,Poslusny N,Rachagani S,Ranganathan S,Razpet A,Riggs PK,Rincon G,Rodriguez-Osorio N,Rodriguez-Zas SL,Romero NE,Rosenwald A,Sando L,Schmutz SM,Shen L,Sherman L,Southey BR,Lutzow YS,Sweedler JV,Tammen I,Telugu BP,Urbanski JM,Utsunomiya YT,Verschoor CP,Waardenberg AJ,Wang Z,Ward R,Weikard R,Welsh TH,White SN,Wilming LG,Wunderlich KR,Yang J,Zhao FQ.The genome sequence of taurine cattle: a window to ruminant biology and evolution.Science. 2009;324:522-8.
28. Rajagopal M,Tollner TL,Finkbeiner WE,Cherr GN,Widdicombe JH.Differentiated structure and function of primary cultures of monkey oviductal epithelium.In Vitro Cell Dev Biol Anim. 2006;42:248-54.
29. Yu X,Ng CP,Habacher H,Roy S.Foxj1 transcription factors are master regulators of the motile ciliogenic program.Nat Genet. 2008;40:1445-53.
30. Bowen NJ,Logani S,Dickerson EB,Kapa LB,Akhtar M,Benigno BB,McDonald JF.Emerging roles for PAX8 in ovarian cancer and endosalpingeal development.Gynecol Oncol. 2007;104:331-7.
31. Espey LL.Current status of the hypothesis that mammalian ovulation is comparable to an inflammatory reaction.Biol Reprod. 1994;50:233-8.
32. Richards JS,Russell DL,Ochsner S,Espey LL.Ovulation: new dimensions and new regulators of the inflammatory-like response.Annu Rev Physiol. 2002;64:69-92.
33. Lei K,Chen L,Georgiou EX,Sooranna SR,Khanjani S,Brosens JJ,Bennett PR,Johnson MR.Progesterone Acts via the Nuclear Glucocorticoid Receptor to Suppress IL-1beta-Induced COX-2 Expression in Human Term Myometrial Cells.PLoS One. 2012;7:e50167-e50167.
34. Koch AE,Polverini PJ,Kunkel SL,Harlow LA,DiPietro LA,Elner VM,Elner SG,Strieter RM.Interleukin-8 as a macrophage-derived mediator of angiogenesis.Science. 1992;258:1798-801.
35. Palter SF,Mulayim N,Senturk L,Arici A.Interleukin-8 in the human fallopian tube.J Clin Endocrinol Metab. 2001;86:2660-7.
36. Zhou J,Hsieh JT.The inhibitory role of DOC-2/DAB2 in growth factor receptor-mediated signal cascade. DOC-2/DAB2-mediated inhibition of ERK phosphorylation via binding to Grb2.J Biol Chem. 2001;276:27793-8.
37. Jiang Y,He X,Howe PH.Disabled-2 (Dab2) inhibits Wnt/beta-catenin signalling by binding LRP6 and promoting its internalization through clathrin.EMBO J. 2012;31:2336-49.
38. Majid S,Saini S,Dahiya R.Wnt signaling pathways in urological cancers: past decades and still growing.Mol Cancer. 2012;11:7-7.
39. Mok SC,Chan WY,Wong KK,Cheung KK,Lau CC,Ng SW,Baldini A,Colitti CV,Rock CO,Berkowitz RS.DOC-2, a candidate tumor suppressor gene in human epithelial ovarian cancer.Oncogene. 1998;16:2381-7.
40. Hempel N,Carrico PM,Melendez JA.Manganese superoxide dismutase (Sod2) and redox-control of signaling events that drive metastasis.Anticancer Agents Med Chem. 2011;11:191-201.
41. Dhar SK,St Clair DK.Manganese superoxide dismutase regulation and cancer.Free Radic Biol Med. 2009;52:2209-22.
42. Kurumbail RG,Kiefer JR,Marnett LJ.Cyclooxygenase enzymes: catalysis and inhibition.Curr Opin Struct Biol. 2001;11:752-60.
43. Simmons DL,Botting RM,Hla T.Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition.Pharmacol Rev. 2004;56:387-437.
44. Bertagnolli MM.Chemoprevention of colorectal cancer with cyclooxygenase-2 inhibitors: two steps forward, one step back.Lancet Oncol. 2007;8:439-43.
45. Dempke W,Rie C,Grothey A,Schmoll HJ.Cyclooxygenase-2: a novel target for cancer chemotherapy?.J Cancer Res Clin Oncol. 2001;127:411-7.
46. Keller JJ,Giardiello FM.Chemoprevention strategies using NSAIDs and COX-2 inhibitors.Cancer Biol Ther. 2003;2:S140-9.
47. Garten A,Petzold S,Korner A,Imai S,Kiess W.Nampt: linking NAD biology, metabolism and cancer.Trends Endocrinol Metab. 2009;20:130-8.